ReviewPaediatric drugs2017
Current Management of Childhood Acute Myeloid Leukemia.
Review in Paediatric drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Paediatric acute myeloid leukaemia epidemiology, treatment approaches, and outcomes in africa: A review of the literature.BMC cancer · 2025Pooled it
- Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Article
- Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil.Cancer reports (Hoboken, N.J.) · 2026Article
- A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia.Cell reports. Medicine · 2024Article
- Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead.Cureus · 2024Review
- Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.NPJ precision oncology · 2024Article
- In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.Scientific reports · 2024Article
- Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.Bone marrow transplantation · 2024Article
- Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 × 10International journal of hematology · 2023Article
- Using published pathway figures in enrichment analysis and machine learning.BMC genomics · 2023Article
- A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group.Leukemia · 2023Article
- Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.Blood advances · 2023Article
- Analysis of rare driving events in pediatric acute myeloid leukemia.Haematologica · 2023Article
- A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia.Molecular and clinical oncology · 2022Article
- Article
- Silencing of circTASP1 inhibits proliferation and induces apoptosis of acute myeloid leukaemia cells through modulating miR-515-5p/HMGA2 axis.Journal of cellular and molecular medicine · 2021Article
- [Unrelated cord blood stem cell transplantation for high-risk/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- A three-gene signature and clinical outcome in pediatric acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outcome for children with acute myeloid leukemia (AML) has improved significantly over the past 30 years, with complete remission and overall survival rates exceeding 90 and 60%, respectively, in recent clinical trials. However, these improvements have not been achieved by the introduction of new agents. Instead, intensification of standard chemotherapy, more precise risk classification, improvements in supportive care, and the use of minimal residual disease to monitor response to therapy have all contributed to this success. Nevertheless, novel therapies are needed, as the cure rates for many subtypes of childhood AML remain unacceptably low. Here, we briefly review advances in our understanding of the biology and genetics of AML, the results of recent clinical trials, and current recommendations for the treatment of children with AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.